DepakoteBirthInjury.com Discusses the New England Journal of Medicine Study That Offers Potential Link between Use of Depakote During Pregnancy and Harm to a Child’s IQ

Share Article

A study published in the April 16, 2009 issue of the New England Journal of Medicine and entitled, "Cognitive Function at 3 Years of Age after Fetal Exposure to Antiepileptic Drugs" offers a potential link between the use of Depakote while pregnant and the potential for a lower IQ in the children who were exposed to it while in the womb. The team of professionals at DepakoteBirthInjury.com, whose Web site can be found at http://www.depakotebirthinjury.com, in its efforts as a free online resource for consumers who have encountered problems with using this medication, hereby shares these results of this Depakote study.

“This finding supports a recommendation that valproate not be used as a first-choice drug in women of childbearing potential.”

The team of professionals at DepakoteBirthInjury.com, a free online resource for consumers that details the alleged problems related to use of the medication while pregnant, hereby discusses The New England Journal of Medicine study published the in its April 16, 2009 publication entitled, "Cognitive Function at 3 Years of Age after Fetal Exposure to Antiepileptic Drugs" that reviewed the IQ levels of children who were three years old at the time. The study compared children who were exposed to Depakote while their mothers were pregnant to children who were exposed to Tegretol and Lamictal. The study concluded that the children who were exposed to Depakote while their mothers were pregnant had IQ levels that were between 6 and 9 points lower than the children who were exposed to the other medications.

This study did not include children who were born with alleged Depakote birth defects that have otherwise been linked to the medication that include spina bifida, neural tube malformations and other serious birth defects. The study ran in duration from 1999 until 2004 and involved children in the United States and in England. In its conclusion, the study stated that, “This finding supports a recommendation that valproate not be used as a first-choice drug in women of childbearing potential.”

Depakote has been used as a medication to treat medical conditions that include the manic episodes associated with bipolar disorder, epilepsy and migraine headaches, and it is considered an anticonvulsant medication that is manufactured by Abbott Laboratories.

About DepakoteBirthInjury.com

DepakoteBirthInjury.com, whose Web site is located at http://www.depakotebirthinjury.com, is a public resource that’s been built and maintained by a group of concerned professionals who want to provide general information for consumers regarding the potential dangers involved with the use of Depakote while pregnant. This resource is not to be considered as medical or legal advice, which should only be dispensed by a licensed medical doctor or a Depakote lawyer.

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Faith Anderson
Visit website